Cohort 2 comprised 237 patients with NSCLC accepted EGFR-TKI target therapy (40% male, stage IV) (Supplementary Table S3), with ages at diagnosis ranging from 26 to 86 years and a median age of 60 years (Table 1). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.